Lombard's H1 "in line" as US Aorfix launch picks up pace
This article was originally published in Clinica
Lombard Medical Technologies’ first-half revenues grew 2% year-on-year to £2.0m ($3.1m), “in line” with Canaccord Genuity analyst Julie Simmonds’ expectations and its previous trading update in July. The firm’s US launch of its flagship Aorfix stent for abdominal aortic aneurysms (AAA) is “well underway” CEO Simon Hubbert told Clinica – the device got the FDA go-ahead in February for use in patients with high-angle aneurysms of up to 90 degrees (www.clinica.co.uk, 18 February 2013).
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.